✦ LIBER ✦

DISPOSITION OF ORALLY ADMINISTERED 13-cis RETINOIC ACID IN MICE

✍ Scribed by D.L. Hill; J.R. Kalin; M.E. Starling

Book ID: 118718792
Publisher: John Wiley and Sons
Year: 1981
Tongue: English
Weight: 95 KB
Volume: 359
Category: Article
ISSN: 0890-6564
DOI: 10.1111/j.1749-6632.1981.tb12769.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral 13-cis retinoic acid is superior to

Oral 13-cis retinoic acid is superior to 9-cis retinoic acid in sebosuppression in human beings

✍ Jean-Marie Geiger; Lucette Hommel; Monika Harms; Jean-Hilaire Saurat 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 274 KB

13-cis Retinoic Acid (Accutane) Suppress

13-cis Retinoic Acid (Accutane) Suppresses Hippocampal Cell Survival in Mice

✍ YASUO SAKAI; JAMES E. CRANDALL; JACOB BRODSKY; PETER MCCAFFERY 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 1023 KB

Progressive 13-cis-retinoic acid dosage

Progressive 13-cis-retinoic acid dosage in the treatment of oral leukoplakia

✍ Toma, S.; Mangiante, P.E.; Margarino, G.; Nicolo, G.; Palumbo, R. 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 378 KB

Disposition and metabolism of 13-cis and

Disposition and metabolism of 13-cis and all-trans-retinoic acid in the plasma of cynomolgus monkeys: A comparison to a human case study with 13-cis-retinoic acid

✍ W. Slikker Jr.; J. Creech-Kraft; J.R. Bailey; L.G. Roberts; B. Fischer; W. Wittf 📂 Article 📅 1990 🏛 Elsevier Science 🌐 English ⚖ 266 KB

Anticlastogenic effects of 13-cis-retino

Anticlastogenic effects of 13-cis-retinoic acid in vitro

✍ Trizna, Zoltán; Hsu, T.C.; Schantz, Stimson P.; Jack Lee, J.; Hong, Waun K. 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 565 KB

13-cis-Retinoic acid in chemopreventiion

13-cis-Retinoic acid in chemopreventiion of superficial bladder cancer

✍ Geroge R. Prout Jr.; Bruce A. Barton; W. W. Kontz Jr.; S. Loening; M. J. Flangan 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 369 KB

Animal studies indicate that 13-cis-retinoic acid (CRA) inhibits bladder tumor growth and is effective in treating patients with serious dermatologic disorders. A trial of CRA in patients at high risk for recurrent Ta, T l tumors was initiated at an experimental dose of 0.5 mg/kg/d in three divided